Protocol Ledger

NCT06745908 · Phase III · RECRUITING

Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Re

Interventional Phase III clinical trial protocol NCT06745908 sponsored by ImmunityBio in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-10-01 Enrollment: 507 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06745908
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)507 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06745908
Protocol FieldVerified Registry Value
NCT IdentifierNCT06745908
Consolidated Lead SponsorImmunityBio
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment507 participants (ESTIMATED)
Registered Start Date2025-10-01
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06745908
Hospital Research SiteLocationSite Profile
Providence Medical FoundationFullerton, CAOpen Hospital Dossier ->
City of Hope Orange CountyIrvine, CAOpen Hospital Dossier ->
Hoag Memorial Hospital PresbyterianNewport Beach, CAOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI